Our CEO, Margaret Keegan, is featured in the December issue of Pharmaceutical Executive candidly discussing the future of clinical development, the changing commercialization sector and the manufacturing of tomorrow’s medicines.
(more…)
Karl Deonanan appointed Chief Financial Officer
Matt DeZee named to newly established role, Chief Transformation and Strategy Officer
Bethesda, Md., October 23, 2024—Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced key leadership changes to support its next phase of growth. This includes the appointment of Karl Deonanan as Chief Financial Officer (CFO). Mr. Deonanan succeeds Matt DeZee, who has served as CFO of Precision since 2020 and will be transitioning to the newly created role of Chief Transformation and Strategy Officer (CTSO), effective immediately.
— Founding CEO Mark Clein named Executive Chairman; Mr. Clein and co-founder Ethan Leder to continue as Board Directors —
BETHESDA, MD., October 1, 2024 – Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced the appointment of Margaret Keegan as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately. Ms. Keegan succeeds Mark Clein, who is assuming the role of Executive Chairman. Mr. Clein co-founded Precision in 2012 as CEO and, together with co-founder Ethan Leder, purpose-built Precision to capitalize on the scientific and technological innovations that are transforming drug development and enabling widespread access to new, breakthrough therapies. Mr. Leder formerly served as Executive Chairman and will remain a member of the Board of Directors.
Houston is one of seven global Precision specialty labs addressing the rising demand for rapid, comprehensive biomarker data to support the development of advanced therapies and diagnostics
HOUSTON, Tx., April 12, 2023 – Precision for Medicine, the first global biomarker-driven clinical research organization, today announced the expansion of its cell biology and genomics laboratory in Houston, TX, proliferating the company’s global biomarker capabilities and laboratory operations.
